Aromasin
(Exemestane)ApprovedSmall molecule
PfizerExemestane is used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by blocking the production of estrogen, which can fuel the growth of certain breast cancers.[2] Aromasin is currently approved and in use across 22 indications[4].[1]
Aromasin is one of 382 small molecule programs targeting Breast Cancer. It is currently in Approved.
22
Indications
205
Total Trials
39
Active Trials
381
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Aromasin
PfizerApproved
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer141 trials
Show 138 more trials
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002777·342 enrolled
Breast Cancer, Sexuality and Black Cohosh
Unknown status·IIrmandade da Santa Casa de Misericordia de Sao Paulo·Phase 4·NCT02467686·60 enrolled
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Unknown status·OOrganisation for Oncology and Translational Research·Phase 2·NCT02025712·35 enrolled
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
Unknown status·—·Phase 3·NCT03137368·300 enrolled
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
Unknown status·—·Phase 2·NCT02917005·160 enrolled
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Completed·—·Phase 2·NCT02648477·30 enrolled
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Completed·—·Phase 2·NCT01594216·25 enrolled
ER Reactivation Therapy for Breast Cancer
Completed·—·Phase 2·NCT02188745·19 enrolled
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Completed·—·Phase 2·NCT00810797·36 enrolled
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Active, not recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
Postmenopausal Women5 trials
Endocrine Therapy3 trials
Early Breast Cancer3 trials
Breast Neoplasms3 trials
38 more indications
TED2 trials
Non-Small Cell Lung Cancer2 trials
Steroid2 trials
Menopausal Women2 trials
Adjuvant2 trials
Ovarian Cancer2 trials
Randomized1 trial
Prospective1 trial
Endometrial Carcinoma1 trial
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Completed·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 2·NCT01965080·52 enrolled
Observational Study1 trial
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Unknown status·—··NCT04852081·1,000 enrolled
Patient Preference1 trial
Metastatic Solid Tumors1 trial
Tic Disorder1 trial
Prostate Cancer1 trial
Prevention1 trial
Pancreatic Cancer1 trial
Bone Metastasis1 trial
Intraepithelial Neoplasia1 trial
ER Positive Breast Cancer1 trial
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05512364·220 enrolled
Breast Adenocarcinoma1 trial
Anatomic Stage 0 Breast Cancer AJCC v81 trial
Advanced Breast Cancer1 trial
Malignant Neoplasm1 trial
Metastatic Breast Cancer1 trial
Breast Ductal Carcinoma in Situ1 trial
Advanced or Metastatic Breast Cancer1 trial
Cystic1 trial
Locally Advanced or Metastatic Breast Cancer1 trial
Anatomic Stage III Breast Cancer AJCC v81 trial
Adult Ovarian Granulosa Cell Tumor1 trial
Ductal Carcinoma in Situ1 trial
Unspecified2 trials
Palbociclib With Everolimus + Exemestane In BC
Completed·—·Phase 1/2·NCT02871791·41 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 21, 1999
AROMASIN
NDA NDA020753
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aromasin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Exemestane. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]